Curve Therapeutics Ltd has named Andre Hoekema as chair of the board and added to its management with the appointments of Rab Prinjha as chief R&D officer and Cora Griffin as head of business development. Curve is expanding its leadership team to advance the biotech company’s discovery platform and therapeutic pipeline and to expand pharma relationships. The new chair brings four decades of experience in the biotech industry, including as chief business officer at Galapagos Pharma for 18 years, and is a board member at Artax Biopharma, Fibrocor Therapeutics and Mimetas BV. Dr Prinjha, who has a PhD in molecular cell biology, joins Curve from GSK and will be responsible for the therapeutic portfolio strategy to advance its pipeline, including a dual HIF-1/HIF-2 inhibitor and an inhibitor of ATIC homodimerization.
Curve Therapeutics announced the appointments on 2 October and 9 October 2024.
Copyright 2024 Evernow Publishing Ltd.